Cycloalkano(1,2-B)indole-sulphonamides, pharmaceutical compositions and use

ABSTRACT

Cycloalkano[1,2-b]indole-sulphonamides of the formula ##STR1## where appropriate in an isomeric form, and their salts are disclosed. These compounds are useful to inhibit platelet aggregation and to antoganize thromboxane A 2 .

This is a division of application Ser. No. 308,152, filed Feb. 8, 1989,now U.S. Pat. No. 4,904,797, which is a division of Ser. No. 212,840,filed June 29, 1988, now U.S. Pat. No. 4,827,032, which is acontinuation of Ser. No. 013,302, filed Feb. 10, 1987, now abandoned.

The invention relates to new cycloalkano[1,2-b]-indole-silphonamides, toprocess for their preparation and to their use in medicaments.(Benzenesulphonamidoalkyl)-cycloalkano[1,2-b]indoles, which are likewisenew, can be used as intermediates for the preparation of the newcompounds.

New cycloalkano[1,2-b]indole-sulphonamides of the general formula (I)##STR2## in which

R¹ represents hydrogen, halogen, trifluoromethyl, carboxyl oralkoxycarbonyl; or represents a group of the formula --S(O)_(m) R³,

in which

R³ denotes alkyl or aryl, and

m denotes one of the numbers 0, 1 or 2; or represents a group of theformula ##STR3## in which

R⁴ and R⁵ are identical or different and represent hydrogen, alkyl,aryl, aralkyl or acetyl; or represents a group of the formula --OR⁶,

in which

R⁶ denotes hydrogen, alkyl, aryl, aralkyl, alkyl-SO₂ --, aryl-SO₂ --,aralkyl-SO₂ -- or trifluoromethyl; or represents alkyl, alkenyl orcycloalkyl, each of which is optionally substituted by carboxyl,alkoxycarbonyl, halogen, hydroxyl, alkoxy, alkylthio or cyano,

R² represents aryl which is optionally substituted up to 5 times byhalogen, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio,alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, alkylthio, hydroxyl,carboxyl, alkoxycarbonyl, phenyl, phenoxy, benzyloxy, benzylthio or by agroup of the formula ##STR4## in which

R⁴ and R⁵ have the abovementioned meaning,

x represents the number 1, 2 or 3, and

y represents the number 0 or 1,

where appropriate in an isomeric form, and their salts, have been found.

The cycloalkano[1,2-b]indole-sulphonamides according to the inventionhave several asymmetric carbon atoms and can thus exist in varioussterochemical forms. The invention relates both to the individualisomers and to the mixtures thereof.

The following isomeric forms of thecycloalkano[1,2-b]indole-sulphonamides may be mentioned by way ofexample: ##STR5## R¹, R², x and y having the abovementioned meaning.

The cycloalkano[1,2-b]indole-sulphonamides according to the inventioncan also be in the form of their salts. In general, the salts which maybe mentioned in this context are those with organic or inorganic bases.

Physiologically acceptable salts are preferred within the scope of thepresent invention. Physiologically acceptable salts of thecycloalkano[1,2-b]indole-sulphonamides can be metal or ammonium salts ofthe substances according to the invention which have a free carboxylgroup. Examples of those which are particularly preferred are sodium,potassium, magnesium or calcium salts, as well as ammonium salts whichare derived from ammonia or organic amines such as, for example,ethylamine, di- or triethylamine, di- or triethanolamine,dicyclohexylamine, dimethylaminoethanol, arginine or ethylenediamine.

The substances according to the invention surprisingly exhibit an actioninhibiting platelet aggregation and can be used for the therapeutictreatment of humans and animals.

Alkyl generally represents a straight-chain or branched hydrocarbonradical having 1 to 12 carbon atoms alkyl having 1 to 6 carbon atoms ispreferred. Examples which may be mentioned are methyl, ethyl, propyl,isopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, isohexyl, heptyl,isoheptyl, octyl and isooctyl.

Alkenyl generally represents a straight-chain or branched hydrocarbonradical having 2 to 12 carbon atoms and one or more, preferably havingone or two, double bonds. The lower alkenyl radical having 2 to 6 carbonatoms and one double bond is preferred. An alkenyl radical having 2 to 4carbon atoms and one double bond is particularly preferred. Exampleswhich may be mentioned are vinyl, allyl, propenyl, isopropenyl, butenyl,isobutenyl, pentenyl, isopentenyl, hexenyl, isohexenyl, heptenyl,isoheptenyl, octenyl and isooctenyl.

Cycloalkyl generally represents a cyclic hydrocarbon radical having 3 to8 carbon atoms. The cyclopentane and the cyclohexane ring is preferred.Examples which may be mentioned are cyclopropyl, cyclopentyl,cyclohexyl, cycloheptyl and cyclooctyl.

Alkoxy generally represents a straight-chain or branched hydrocarbonradical which has 1 to 12 carbon atoms and is bonded via an oxygen atom.Lower alkoxy having 1 to 6 carbon atoms is preferred. An alkoxy radicalhaving 1 to 4 carbon atoms is particularly preferred. Examples which maybe mentioned are methoxy, ethoxy, propoxy, isopropxy, butoxy, isobutoxy,pentoxy, isopentoxy, hexoxy, isohexoxy, heptoxy, isoheptoxy, octoxy orisooctoxy.

Alkylthio generally represents a straight-chain or branched hydrocarbonradical which has 1 to 12 carbon atoms and is bonded via a sulphur atom.Lower alkylthio having 1 to 6 carbon atoms is preferred. An alkylthioradical having 1 to 4 carbon atoms is particularly preferred. Exampleswhich may be mentioned are methylthio, ethylthio, propylthio,isopropylthio, butylthio, isobutylthio, pentylthio, isopentylthio,hexylthio, isohexylthio, heptylthio, isoheptylthio, octylthio andisooctylthio.

Aryl generally represents an aromatic radical having 6 to 12 carbonatoms. Preferred aryl radicals are phenyl, naphthyl and diphenyl.

Aralkyl generally represents an aryl radical which has 7 to 14 carbonatoms and is bonded via an alkylene chain. Aralkyl radicals having 1 to6 carbon atoms in the aliphatic part and 6 to 12 carbon atoms in thearomatic part are preferred. Examples which may be mentioned are thefollowing aralkyl radicals: benzyl, naphthylmethyl, phenethyl andphenylpropyl.

Alkoxycarbonyl can be represented by, for example, the formula ##STR6##In this, alkyl represents a straight-chain or branched hydrocarbonradical having 1 to 8 carbon atoms. Lower alkoxycarbonyl having 1 to 6carbon atoms in the alkyl part is preferred. An alkoxycarbonyl having 1to 4 carbon atoms in the alkyl part is particularly preferred Exampleswhich may be mentioned are the following alkoxycarbonyl radicals:methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl,butoxycarbonyl and isobutoxycarbonyl.

Carboxyalkyl generally represents a straight-chain or branchedhydrocarbon radical which has 1 to 12 carbon atoms and is substituted bya carboxyl group. Carboxy-lower-alkyl having 1 to 6 carbon atoms ispreferred. Examples which may be mentioned are: carboxymethyl,1-carboxyethyl, 1-carboxypropyl, 1-carboxybutyl, 1-carboxypentyl,1-carboxyhexyl, 2-carboxyethyl, 2-carboxypropyl, 2-carboxybutyl,3-carboxypropyl, 3-carboxybutyl, 4-carboxybutyl; 2-carboxy-1-propyl and1-carboxy-1-propyl.

Alkoxycarbonylalkyl generally represents a straight-chain or branchedhydrocarbon radical which has 1 to 12 carbon atoms and is substituted byan alkoxycarbonyl group, alkoxylcarbonyl having the abovementionedmeaning. Lower alkoxycarbonyl-lower-alkyl having 1 to 6 carbon atoms ineach alkyl part is preferred. Examples which may be mentioned are:methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl,butoxycarbonylmethyl, isopropoxycarbonylmethyl, isobutoxycarbonylmethyl,1-methoxycarbonylethyl, 1-ethoxycarbonylethyl, 1-propoxycarbonylethyl,1-butoxycarbonylethyl, 1-isopropoxycarbonylethyl,1-isobutoxycarbonylethyl, 2-methoxycarbonylethyl, 2-ethoxycarbonylethyl,2-propoxycarbonylethyl, 2-butoxycarbonylethyl,2-isopropoxycarbonylethyl, 2-isobutoxycarbonylethyl,3-methoxycarbonylpropyl, 3-ethoxycarbonylpropyl,3-isopropoxycarbonylpropyl and 3-isobutoxycarbonylpropyl

Halogen generally represents fluorine, chlorine, bromine or iodine,preferably fluorine, chlorine or bromine. Halogen particularlypreferably represents fluorine or chlorine.

The compounds of the general formula (I) which are preferred are thosein which

R¹ represents hydrogen, fluorine, chlorine, bromine, trifluoromethyl,carboxyl or lower alkoxycarbonyl; or represents a group of the formula

    --S(O).sub.m R.sup.3

in which

R³ denotes lower alkyl or phenyl, and

m denotes a number 0 or 2; or represents a group of the formula ##STR7##in which

R⁴ and R⁵ are identical or different and denote hydrogen, lower alkyl,phenyl, benzyl or acetyl; or represents a group of the formula --OR⁶, inwhich

R⁶ denotes hydrogen, lower alkyl, phenyl, phenyl-SO₂ --, methyl-SO₂ --,ethyl-SO₂ -- or trifluoromethyl; or represents lower alkyl, loweralkenyl, cyclopentyl, or cyclohexyl, each of which is optionallysubstituted by carboxyl, methoxycarbonyl, ethoxycarbonyl, fluorine,chlorine, bromine, hydroxyl, lower alkoxy or cyano.

R² represents phenyl which is optionally substituted up to three timesby fluorine, chlorine, bromine, cyano, trifluoromethyl,trifluoromethoxy, trifluoromethylthio, lower alkyl, carboxymethyl,carboxyethyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl,lower alkoxy, lower alkylthio, hydroxyl, carboxyl, lower alkoxycarbonyl,phenyl, phenoxy, benzyloxy, benzylthio or by the group ##STR8## in which

R⁴ and R⁵ have the meaning already indicated,

x represents the number 1, 2 or 3, and

y represents the number 0 or 1,

where appropriate in an isomeric form, and their salts.

The compounds of the general formula (I) which are particularlypreferred are those in which

R¹ represents hydrogen, fluorine, chlorine, bromine, trifluoromethyl,methylthio, ethylthio, methylsulphonyl, phenylthio, phenylsulphonyl,amino, dimethylamino, diethylamino or acetylamino; or represents a groupof the formula

    --OR.sup.6,

in which

R⁶ denotes hydrogen, C₁ -C₄ -alkyl, phenyl or benzyl;

or represents C₁ -C₄ -alkyl,

R² represents phenyl which is substituted up to three times, identicallyor differently, by fluorine, chlorine, bromine, cyano, trifluoromethyl,trifluoromethoxy, C₁ -C₄ -alkyl, C₁ -C₄ -alkoxy, methylthio, hydroxyl,methoxycarbonyl, ethoxycarbonyl, dimethylamino, acetylamino, ordiethylamino,

x represents the number 1 or 2, and

y represents the number 0 or 1,

where appropriate in an isomeric form, and their salts.

The compounds of the general formula (I) which are very particularlypreferred are those in which

R¹ represents hydrogen, fluorine, methyl, methoxy, benzyloxy orhydroxyl,

R² represents phenyl which is substituted by fluorine, chlorine,trifluoromethyl, methyl, ethyl, propyl, isopropyl or methoxy,

x represents the number 1 or 2, and

y represents the number 0 or 1,

where appropriate in an isomeric form, and their salts.

Particularly preferred are (+)- or (-)-isomericcycloalkano[1,2-b]indole-sulphonamides of the formula ##STR9## in which

R¹ represents hydrogen, fluorine, methyl, methoxy, benzyloxy orhydroxyl,

R² represents phenyl which is substituted by fluorine, chlorine,trifluoromethyl, methyl, propyl, isopropyl or methoxy, and

y represents the number 0 or 1, and their salts.

The following cycloalkano[1,2-b]indole-sulphonamides may be mentioned byway of example:

1-(benzenesulphonamidomethyl)-4-(2-carboxyethyl)cyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-fluorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-chlorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole

1-(benzenesulphonamidomethyl)-4-(2-carboxyethyl)-7-methoxycyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-fluorophenylsulphonamidomethyl)-7-methoxycyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-chlorophenylsulphonamidomethyl)-7methoxycyclopentano[1,2-b]indole

1-(benzenesulphonamido)-4-(2-carboxyethyl)cyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-fluorophenylsulphonamido)cyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-chlorophenylsulphonamido)cyclopentanto[1,2-b]indole

1-(benzenesulphonamido)-4-(2-carboxyethyl)-7-methoxycyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-fluorophenylsulphonamido)-7-methoxycyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-chlorophenylsulphonamido)-7-methoxycyclopentano[1,2-b]indole

1-(benzenesulphonamidomethyl)-4-(2-carboxyethyl)-7-methylcyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-fluorophenylsulphonamidomethyl)-7-methylcyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-chlorophenylsulphonamidomethyl)-7methylcyclopentano[1,2-b]indole

1-(benzenesulphonamido)-4-(2-carboxyethyl)-7-methylcyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-fluorophenylsulphonamido)-7-methylcyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-chlorophenylsulphonamido)-7-methylcyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-tolylsulphonamidomethyl)-cyclopentano[1,2-b]indole

4-(2-carboxyethyl)-1-(4-tolylsulphonamido)-cyclopentano1,2-b]indole

3-r-(benzenesulphonamido)-9-(2-carboxyethyl)-6-methoxy1,2,3,4,4a-t,9a-t-hexahydrocarbazole

3-r-(benzenesulphonamido)-9-(3-carboxyethyl)-6-methoxy1,2,3,4,4a-c,9a-c-hexahydrocarbazole

3-r-(benzenesulphonamidomethyl)-9-(2-carboxyethyl)1,2,3,4,4a-t,9a-t-hexahydrocarbazole

3-r-(benzenesulphonamidomethyl)-9-(2-carboxyethyl)1,2,3,4,4a-c,9a-c-hexahydrocarbazole

3-r-(benzenesulphonamidomethyl)-9-(2-carboxyethyl)-6-methoxy-1,2,3,4,4a-t,9a-t-hexahydrocarbazole

3-r-(benzenesulphonamidomethyl)-9-(2-carboxyethyl)-6-methoxy-1,2.3,,4,4a-c,9a-c-hexahydrocarbazole

9-(2-carboxyethyl)-3-r-(4-chlorophenylsulphonamido)-1,2,3,4,4a-t,9a-t-hexahydrocarbazole

9-(2-carboxyethyl)-3-r-(4-chlorophenylsulphonamido)-1,2,3,4,4a-c,9a-c-hexahydrocarbazole

9-(2-carboxyethyl)-3-r-(4-fluorophenylsulphonamido)-1,2,3,4,4a-t,9a-t-hexahydrocarbazole

9-(2-carboxyethyl)-3-r-(4-fluorophenylsulphonamido)-1,2,3,4,4a-c,9a-c-hexahydrocarbazole,

9-(2-carboxyethyl)-3-r-(4-tolylsulphonamido)-1,2,3,4,4a-t,9a-t-hexahydrocarbazole

9-(2-carboxyethyl)-3-r-(4-tolylsulphonamido)-1,2,3,4,4a-c,9a-c-hexahydrocarbazole

9-(2-carboxyethyl)-3-r-(4-fluorophenylsulphonamido)-6-methoxy-1,2,3,4,4a-t,9a-t-hexahydrocarbazole

9-(2-carboxyethyl)-3-r-(4-fluorophenylsulphonamido)-6-methoxy-1,2,3,4,4a-c-9a-c-hexahydrocarbazole

(+)-3-(4-chlorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole

(+)-3-(4-fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole

(-)-3-(4-chlorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole

(-)-3-(4-fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole

(±)-3-(4-chlorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,,3,4-tetrahydrocarbazole

(±)-3-(4-fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole.

Particularly preferred are:

(+)-3-(4-fluorophenyl-sulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazoleand

(-)-3-(4-fluorophenyl-sulphonamido)-9-(2-carbonylethyl)-1,2,3,4-tetrahydrocarbazole.

Furthermore, a process for the preparation of thecycloalkano[1,2-b]indole-sulphonamides according to the invention, andof their salts, has been found, which is characterized in that(benzenesulphonamidoalkyl)cycloalkano[1,2-b]indoles of the generalformula (XIII) ##STR10## in which

R¹ represents hydrogen, halogen, trifluoromethyl, carboxyl oralkoxycarbonyl; or represents a group of the formula --S(O)_(m) R³,

R³ denotes alkyl or aryl, and m denotes one of the numbers 0, 1 or 2; orrepresents a group of the formula ##STR11## in which

R⁴ and R⁵ are identical or different and represent hydrogen, alkyl,aryl, aralkyl or acetyl; or represents a group of the formula --OR⁶,

R⁶ denotes hydrogen, alkyl, aryl, aralkyl, alkyl-SO₂ --, aryl-SO₂ --,aralkyl-SO₂ -- or trifluoromethyl; or represents alkyl, alkenyl orcycloalkyl, each of which is optionally substituted by carboxyl,alkoxycarbonyl, halogen, hydroxyl, alkoxy, alkylthio or cyano,

R² represents aryl which is optionally substituted up to 5 times byhalogen, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio,alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, alkylthio, hydroxyl,carboxyl, alkoxycarbonyl, phenyl, phenoxy, benzyloxy, benzylthio or by agroup of the formula ##STR12## in which

R⁴ and R⁵ have the abovementioned meaning,

x represents the number 1, 2 or 3, and

y represents the number 0 or 1,

are reacted with acrylonitrile in the presence of an inert solvent,where appropriate in the presence of a base, then the N,N'-biscyanoethylcompounds are hydrolyzed, then, in the case where thecycloalkano[1,2-b]dihydroindole-sulphonamides are being prepared thecycloalkano[1,2-b]indolesulphonamides are hydrogenated, whereappropriate in the presence of an inert solvent, in the presence of anacid and of a reducing agent, where appropriate the isomers areseparated in a customary manner, and then, where appropriate, in thecase where the salts are being prepared reaction with an appropriatebase is carried out.

The process according to the invention can be illustrated by the diagramwhich follows: ##STR13##

The cycloalkano[1,2-b]dihydroindole-sulphonamides within the scope offormula (I) correspond to the formula (Ia) ##STR14## in which

R¹, R², x and y have the abovementioned meaning.

When the process according to the invention is carried out, in generalthe intermediates produced can be isolated. Thus, it is possible tocarry out the process according to the invention in several processstages. However, it may also be possible to combine various processsteps.

Possible solvents for the process according to the invention are waterand organic solvents which do not change under the reaction conditions.These preferably include alcohols such as methanol, ethanol, propanol orisopropanol, ethers such as diethyl ether, tetrahydrofuran, dioxane,glycol monomethyl or dimethyl ether, hydrocarbons such as benzene,toluene, xylene, cyclohexane, hexane or petroleum fractions, dimethylsulphoxide, dimethylformamide, hexamethylphosohoric trlamide, ethylacetate, acetonitrile or pyridine. It is equally possible to usemixtures of the said solvents.

Possible bases for the process according to the invention are customarybasic compounds. These preferably include alkali metal and alkalineearth metal hydroxides, such as lithium hydroxide, sodium hydroxide,potassium hydroxide or barium hydroxide, alkali metal hydrides such assodium hydride, alkali metal or alkaline earth metal carbonates such assodium carbonate, potassium carbonate, or alkali metal alcoholates suchas, for example, sodium methanolate or ethanolate, potassium methanolateor ethanolate, or potassium tert.-butylate, or amides such as sodamideor lithium diisopropylamide, or organic amines such asbenzyltrimethylammonium hydroxide, tetrabutylammonium hydroxide,pyridine, triethylamine or N-methylpiperidine.

The process according to the invention is generally carried out in atemperature range from 0° C. to 150° C., preferably from 20° C. to 100°C.

The process according to the invention is generally carried out underatmospheric pressure. However, it is also possible to carry out theprocess under reduced pressure or elevated pressure (for example in arange from 0.5 to 5 bar).

In general, 1 to 20 mol, preferably 1 to 10 mol, of acrylonitrile isused for each mol of (benzenesulphonamidoalkyl)cycloalkano[1,2-b]indole.

The N,N'-bis-cyanoethyl compounds are hydrolyzed in a manner known perse in the presence of bases such as alkali metal or alkaline earth metalhydroxides or alkanolates, in inert solvents such as water or alcohols.The preferred bases which are used are sodium, potassium or bariumhydroxide, sodium methanolate, potassium methanolate, sodium ethanolateor potassium ethanolate, preferably in water or methanol, ethanol,propanol or isopropanol, or in mixtures of these solvents.

In general 1 to 100 mol, preferably 2 to 50 mol, of base is used foreach mol of N,N'-biscyanoethyl compound.

The hydrolysis is carried out in a temperature range from 0° C. to 100°C., preferably from 20° C. to 80° C.

The hydrogenation is carried out in a manner known per se. It ispossible for the acid which is used to be employed as solvent for this.

Suitable solvents for the hydrogenation are inert organic solvents whichdo not change under the reaction conditions. These preferably includeethers such as diethyl ether, dioxane or tetrahydrofuran, or glacialacetic acid, trifluoroacetic acid, methanesulphonic acid ortrifluoromethanesulphonic acid.

Acids which can be used for all the process steps according to theinvention are organic acids. These preferably include carboxylic acidssuch as, for example, acetic acid, propionic acid, chloroacetic acid,dichloroacetic acid or trifluoroacetic acid, or sulfonic acids such as,for example, methanesulphonic acid, ethanesulphonic acid,toluenesulphonic acid or benzenesulphonic acid ortrifluoromethanesulphonic acid.

Suitable reducing agents for the hydrogenation according to theinvention are the customary reducing agents. These preferably includehydrides such as, for example, sodium borohydride, sodiumcyanoborohydride, tetrabutylammonium borohydride, tetrabutylammoniumcyanoborohydride, tributyltin hydride, triethylsilane,dimethylphenylsilane or triphenylsilane.

The hydrogenation is generally carried out in a temperature range from-40° C. to +80° C., preferably from -20° C. to +60° C.

The (benzenesulphonamidoalkyl)cycloalkano[1,2-b]indoles of the generalformula XIII which are used are new. A process for the preparation ofthe (benzenesulphonamidoalkyl) cycloalkano[1,2-b]indoles has likewisebeen found, which is characterized in that phenylhydrazines of thegeneral formula (XIV) ##STR15## in which

R¹ has the abovementioned meaning, are reacted withcycloalkanonesulphonamides of the general formula (XV) ##STR16## inwhich

R², x and y have the abovementioned meaning, in the presence of inertsolvents and, where appropriate, in the presence of a catalyst.

The preparation of the(benzenesulphonamidoalkyl)cycloalkano[1,2-b]indoles according to theinvention can be illustrated by the diagram which follows: ##STR17##

Possible solvents for the process according to the invention here areinert organic solvents which do not change under the reactionconditions. These preferably include alcohols such as, for example,methanol, ethanol, n-propanol, iso-propanol and glycol, ethers such as,for example, diethyl ether, dioxane, tetrahydrofuran, glycol monomethylor dimethyl ether, halogenated hydrocarbons such as di-, tri- ortetrachloromethane, dichloroethylene and trichloroethylene, ethylacetate, toluene, acetonitrile, glacial acetic acid,hexamethylphosphoric triamide, pyridine and acetone. Of course, it ispossible to use mixtures of the solvents.

Suitable catalysts for the process according to the invention are thecustomary acids or Lewis acids. These preferably include inorganic acidssuch as hydrochloric acid, hydrobromic acid or sulphuric acid, ororganic acids such as carboxylic acids or sulphonic acids, for exampleacetic acid, methanesulphonic acid and toluenesulphonic acid, or Lewisacids such as, for example, zinc chloride, zinc bromide or borontrifluoride etherate.

The process according to the invention is generally carried out in atemperature range from 0° C. to 200° C., preferably from 20° C. to 150°C.

The process according to the invention is generally carried out underatmospheric pressure. It is equally possible to carry it out underelevated or reduced pressure (for example from 0.5 to 5 bar).

In general, the hydrazine is used in an amount of 1 to 3 mol, preferably1 to 1.5 mol, relative to the ketone.

Examples of hydrazines which are used for the process according to theinvention are: phenylhydrazine, 4-methoxyphenylhydrazine,4-chlorophenylhydrazine, 4-fluorophenylhydrazine and4-methylphenylhydrazine.

Examples of ketones which are used according to the invention are:

3-(benzenesulphonamidomethyl)cyclopentanone

3-(benzenesulphonamidomethyl)cyclohexanone

4-(benzenesulphonamidomethyl)cyclohexanone

3-(benzenesulphonamido)cyclopentanone

3-(benzenesulphonamido)cyclohexanone

4-(benzenesulphonamido)cyclohexanone

3-(4-chlorophenylsulphonamidomethyl)cyclopentanone

3-(4-fluorophenylsulphonamidomethyl)cyclopentanone

3-(4-methylphenylsulphonamidomethyl)cyclopentanone

3-(4-chlorophenylsulphonamidomethyl)cyclohexanone

3-(4-fluorophenylsulphonamidomethyl)cyclohexanone

3-(4-methylphenylsulphonamidomethyl)cyclohexanone

4-(4-chlorophenylsulphonamidomethyl)cyclohexanone

4-(4-fluorophenylsulphonamidomethyl)cyclohexanone

4-(methylphenylsulphonamidomethyl)cyclohexanone

3-(4-chlorophenylsulphonamido)cyclopentanone

3-(4-fluorophenylsulphonamido)cyclopentanone

3-(4-methylphenylsulphonamido)cyclopentanone

3-(4-chlorophenylsulphonamido)cyclohexanone

3-(4-fluorophenylsulphonamido)cyclohexanone

3-(4-methylphenylsulphonamido)cyclohexanone

4-(4-chlorophenylsulphonamido)cyclohexanone

4-(4-fluorophenylsulphonamido)cyclohexanone

4-(4-methylphenylsulphonamido)cyclohexanone

The hydrazines XIV which are used as starting materials are known or canbe prepared by known methods (compare Houben-Weyl, "Methoden derorganischen Chemie" (Methods of Organic Chemistry), X/2, page 1, 123,(693).

Some of the cyclohexanonesulphonamides of the general formula (XVa)##STR18## in which

y and R² have the abovementioned meaning, which are used as startingmaterials are known, and they can be prepared by methods known per se(compare Houben-Weyl "Methoden der organischen Chemie", IX, 605; A.Mooradian et al., J. Med. Chem. 20 (4), 487 (1977)).

The cyclopentanonesulphonamides of the general formula (XVb) ##STR19##in which

y and R² have the abovementioned meaning, which are used as startingmaterials are novel.

A process for the preparation of the new cycloalkanonesulphonamides hasalso been found, which is characterized in that cycloalkanols of thegeneral formula (XVI) ##STR20## in which

x and y have the abovementioned meaning, are reacted with sulphonylhalides of the general formula (XVII)

    Hal--SO.sub.2 --R.sup.2                                    (XVII),

in which

R² has the abovementioned meaning and

Hal represents fluorine, chlorine, bromine or iodine, preferablychlorine or bromine,

in inert organic solvents and, where appropriate, in the presence ofbases, and then oxidation in inert solvents is carried out.

The cycloalkanols can be prepared by reacting cycloalkenones (XVIII)##STR21## with nitromethane in inert organic solvents, where appropriatein the presence of bases, and then reducing the compounds (XIX)##STR22## (CA 92, 89 849 and CA 87, 22 191).

The sulphonyl halides can be prepared by methods known per se(Houben-Weyl's "Methoden der organischen Chemie" IX, 564).

The preparation of the cycloalkano[1,2-b]indolesulphonamides accordingto the invention can be illustrated by the following reaction diagram:##STR23##

According to this, in the first step (a) cycloalkenones are reacted withnitro compounds such as nitromethane, in inert solvents such asalcohols, for example methanol, ethanol or propanol, or ethers, forexample diethyl ether, tetrahydrofuran or dioxane, or chlorinatedhydrocarbons, for example methylene chloride, chloroform or carbontetrachloride, in the presence of bases such as, for example, sodiumhydride, sodium or potassium methanolate, sodium or potassiumethanolate, potassium tert.-butanolate,1,5-diazabicyclo[4.3.0]non-5-ene, 1,5-diazabicyclo[5.4.0]undec-5-ene,pyridine or triethylamine, at temperatures in the range from 0° C. to100° C., to give nitro compounds.

In step (b) the nitro compounds are reduced in inert solvents such asethers, for example tetrahydrofuran, dioxane or diethyl ether, in thepresence of a reducing agent such as hydrides, for example LiAlH₄,Na[Al(OCH₂ CH₂ --OCH₃)₂ H₂ ] or di-iso-butyl-aluminum-hydrid, attemperatures in the range From -20° C. to -60° C. to give cycloalkanols.

In step (c) the cycloalkanols are converted with sulphonyl halides ininert solvents such as ethers, for example dioxane, tetrahydrofuran ordiethyl ether, or chlorinated hydrocarbons such as methylene chloride,chloroform or carbon tetrachloride, or ethyl acetate or pyridine, whereappropriate in the presence of bases such as1,5-diazabicyclo[4,3,0]non-5-ene, 1,5-diazabicyclo[5,4,o]undec-5-ene,pyridine or triethylamine, at temperatures from -20° C. to +60° C., intosulphonamides.

In step (d), the sulphonamides are oxidized in inert solvents such aswater, glacial acetic acid, acetone, pyridine or mixtures thereof, withoxidizing agents such as chromium(VI) compounds, for example CrO₃, K₂Cr₂ O₇ or Na₂ Cr₂ O₇, at temperatures from -20° C. to +100° C., to givecycloalkanonesulphonamides.

In step (e) cycloalkanonesulphonamides (XVb) and hydrazines XIV arereacted as described above to give the corresponding(benzenesulphonamidoalkyl)cycloalkano[1,2-b]indoles of the formula XIII##STR24## in which

R¹, R², x and y have the abovementioned meaning.

The enantiomerically pure (benzenesulphonamido)cyclohexano[1,2-b]indolesof the general formula (XIIIa) ##STR25## in which

R¹ and R² have the indicated meaning, are likewise new.

A process for the preparation of the enantiomerically pure(benzenesulphonamido)cyclohexano[1,2-b]indoles has been found, which ischaracterized in that enantiomerically purecyclohexano[1,2-b]indolamines of the general formula (XX) ##STR26## inwhich

R¹ has the indicated meaning, are reacted with sulphonyl halides of thegeneral formula (XVII)

    Hal--SO.sub.2 --R.sup.2                                    (XVII),

in which

R² has the indicated meaning, and

Hal represents fluorine, chlorine, bromine or iodine, preferablychlorine or bromine,

in the presence of inert solvents and, where appropriate, in thepresence of a base.

Suitable solvents for the process are the customary organic solventswhich do not change under the reaction conditions. These preferablyinclude ethers such as diethyl ether, dioxane, tetrahydrofuran or glycoldimethyl ether, or hydrocarbons, such as benzene, toluene, xylene,hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbonssuch as dichloromethane, trichloromethane, tetrachloromethane,dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate,triethylamine, pyridine, dimethyl sulphoxide, dimethylformamide,hexamethylphosphoric triamide, acetonitrile, acetone or nitromethane. Itis equally possible to use mixtures of the said solvents.

Bases for the process can be customary basic compounds. These preferablyinclude alkali metal or alkaline earth metal hydroxides, such as lithiumhydroxide, sodium hydroxide, potassium hydroxide or barium hydroxide, oralkali metal hydrides such as sodium hydride, or alkali metal oralkaline earth metal carbonates such as sodium carbonate, sodiumbicarbonate, potassium carbonate or calcium carbonate, or alkali metalalcoholates such as, for example, sodium methanolate, sodium ethanolate,potassium methanolate, potassium ethanolate or potassium tert.-butylate,or alkali metal amides such as lithium diisopropylamide or sodamide, ororganic amines such as ethyldiisopropylamine, benzyltrimethylammoniumhydroxide, tetrabutylammonium hydroxide, pyridine,dimethylaminopyridine, triethylamine, N-methylpiperidine,1,5-diazabicyclo[4.3.0]non-5-ene or 1,5-diazabicyclo[5.4.0]undec-5-ene.

The process according to the invention is generally carried out in atemperature range of from -30° C. to +150° C., preferably from -20° C.to +80° C.

The process according to the invention is generally carried out underatmospheric pressure. It is equally possible to carry it out underreduced pressure or under elevated pressure (for example in a range from0.5 to 200 bar).

The enantiomerically pure cyclohexano[1,2-b]indolamines of the generalformula (XX) according to the invention are new and can be prepared bythe following synthetic routes A, B or C. ##STR27##

R¹ has the indicated meaning, and

R* represents an enantiomerically pure D-, or L-amino acid residue,preferably the 2S-(chloroacetamido)-3-phenylpropionyl radical ##STR28##

R¹ has the indicated meaning.

Synthetic route A

According to this, in step 1 paracetamol (XXI) is hydrogenated on Raneynickel to give a cis/trans mixture of 4-acetamidocyclohexanol (XXII) asdescribed by Billman, J. H., Buhler, J. A., in J. Am. Chem. Soc. 75,1345 (1953). In step 2 4-acetamidocyclohexanol (XXII) is subjected in aone-pot process after an oxidation with CrO₃ to a Fisher indolesynthesis with phenylhydrazines (XIV), and then the acetyl group isremoved by acid hydrolysis.

This process step is carried out in solvents such as water, acetic acidand/or propionic acid, at temperatures from 0° C. to.+150° C.,preferably from 0° C. to 110° C. The racemic3-amino-1,2,3,4-tetrahydrocarbazoles (XXIII) which are readilyaccessible in this way are converted in step 3 by coupling withderivatives of enantiomerically pure amino acids, where appropriate intheir activated form, into the corresponding diastereomer mixtures whichcan be separated into the individual diastereomers by customary methodssuch as crystallization or column chromatography.

Enantiomerically pure amino acid derivatives which are suitable andpreferred are acetylphenylalanine, N-tert-butoxycarbonylphenylalanine,chloroacetylphenylalanine, carbo-benzoxyphenylalanine,methoxy-phenylacetic acid or acetoxy-phenylacetic acid, preferablyN-chloroacetyl-N-phenyl-alanine.

The activating agents which are generally used are the customarypeptide-coupling reagents. These preferably include carbodiimides suchas, for example, diisopropylcarbodiimide, dicyclohexylcarbodiimide orN-(3-dimethylaminoisopropyl)-N'-ethylcarbodiimide hydrochloride, orcarbonyl compounds such as carbonyldiimidazole, or 1,2-oxazoliumcompounds such as 2-ethyl-5-phenyl-1,2-oxazolium 3-sulphonate, orpropanephosphonic anhydride, or isobutyl chloroformate, orbenzotriazolyloxy-tris(dimethylamino)phosphonium hexafluorophosphate, ormethanesulphonyl chloride, where appropriate in the presence of basessuch as triethylamine or N-ethylmorpholine or N-methylpiperidine, ordicyclohexylcarbodiimide and N-hydroxysuccinimide.

The coupling is generally carried out in inert organic solvents,preferably in chlorinated hydrocarbons such as methylene chloride orchloroform, or hydrocarbons such as benzene, toluene, xylene orpetroleum fractions, or in ethers such as dioxane, tetrahydrofuran ordiethyl ether, or in ethyl acetate, dimethylformamide, dimethylsulphoxide or acetone, acetonitrile or nitromethane, at temperaturesfrom -80° C. to +50° C., preferably from -40° C. to +30° C.

After separation of the diastereomer mixtures (XXIV), in step 4 theindividual diastereomers are subjected to acid hydrolysis to give theenantiomerically pure amines (XX).

The hydrolysis is generally carried out with inorganic or organic acidssuch as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoricacid, formic acid, acetic acid, propionic acid, methanesulphonic acid ortrifluoroacetic acid, or mixtures of the said acids.

The solvents which are generally used for this are water or the aqueoussolution of the corresponding acid or mixture of acids which is used.

The hydrolysis is generally carried out in a temperature range from +20°C. to +150° C., preferably from +20° C. to +120° C.

The process according to the invention is generally carried out underatmospheric pressure. It is equally possible to carry it out underreduced or under elevated pressure, for example in an autoclave orpressure tube. It has proved advantageous in this to add thioglycolicacid to the reaction mixture as oxidation inhibitor.

Synthetic route B

According to this, 1,4-cyclohexanedione monoethylene ketal (XXV) isreacted with phenylhydrazines (XIV) in a Fischer indole synthesis togive ketals (XXVI) as described by A. Britten and G Lockwood in J. Chem.Soc., Perkin Trans 1, 1974, 1824-1827.

Hydrolysis of the ketals (XXVI) in step 2 gives the ketones (XXVII)which, in step 3, are converted by reductive amination withS-phenethylamine into the diastereomer mixtures (XXVIII).

The reductive amination is generally carried out with reducing agentssuch as hydrogen, where appropriate in the presence of palladium,platinum, or palladium on animal charcoal as catalyst, or complexhydrides, preferably sodium borohydride, potassium borohydride, lithiumborohydride, zinc borohydride, lithium aluminium borohydride, aluminumhydride; di-iso-butyl-aluminum-hydride, lithium triethylhydridobcrate,sodium cyanotrihydridoborate, tetrabutylammonium cyanotrihydridoborate,tetrabutylammonium hydridoborate, lithium aluminum hydride, sodiumbis[2-methoxyethoxy]dihydridoaluminate or lithiumhydrido-tris[1-methylpropyl]borate in inert solvents such ashydrocarbons, preferably benzene, toluene or xylene, or chlorinatedhydrocarbons such as methylene chloride or chloroform, or ethers such asdiethyl ether, tetrahydrofuran, dioxane or 1,2-dimethoxymethane, oracetonitrile, dimethylformamide, dimethyl sulphoxide or alcohols such asmethanol, ethanol, propanol or isopropanol, in a temperature range from-80° C. to +100° C., preferably -80° C. to +50° C.

The diastereomer mixture (XXVIII) is separated into the individualdiastereomers by customary methods such as chromatography orcrystallization, preferably by crystallization, where appropriate in theform of suitable acid addition products.

Suitable acid addition products in this context are addition products ofthe enantiomers according to the invention with inorganic or organicacids. These preferably include hydrochloric acid, sulphuric acid,phosphoric acid or methanesulphonic acid, benzenesulphonic acid,naphthalenedisulphonic acid or acetic acid, maleic acid, fumaric acid,citric acid or lactic acid.

The removal of the phenylethyl groups in the separated diastereomers(XXVIII) is carried out in step 4 by catalytic transfer hydrogenation togive the enantiomerically pure amines (XX).

Step 4 is generally carried out with reducing agents such as hydrogen,where appropriate in the presence of palladium, palladium on animalcharcoal, or platinum, or ammonium formate, in water or organic solventssuch as alcohols, for example methanol, ethanol, propanol orisopropanol, or dimethyl formamide or dimethyl sulphoxide or mixturesthereof, in a temperature range from 0° C. to +200° C., preferably from+20° C. to 150° C. (L. E. Overman and S. Sugai, J. Org. Chem. 50,4154-4155 (1985).

Synthetic route C

According to this, racemate resolution of the compounds (XXIII) iscarried out by salt formation with optically active acids andcrystallization of these salts, once or several times, from suitablesolvents. The enantiomerically pure compounds (XXIII) are liberated, bytreatment with bases, from the salts which have thus been obtained.

Suitable optically active acids are: (+)-camphorsulphonic acid,(-)-camphorsulphonic acid; (+)-camphor-3-carboxylic acid,(-)-camphor-3-carboxylic acid, (+)-camphoric acid. (-)-camphoric acid,(+)-malic acid, (-)-malic acid, (+)-mandelic acid, (-)-mandelic acid,(+)-lactic acid, (-)-lactic acid,(+)-2-[(phenylamino)carbonyloxy]-propionic acid,(-)-2-[(phenylamino)carbonyloxy]-propionic acid,(-)-αmethoxyphenylacetic acid, (-)-di-O-benzoyltartaric acid,(-)-di-O-4-toluoyltartaric acid, (-)-methoxyacetic acid,(-)-1,1'-binaphthyl-2,2'-diyl-hydrogen phosphate.

Suitable solvents for the crystallization are solvents such as water,alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol,sec-butanol or tert-butanol, ethers such as diethyl ether,tetrahydrofuran, dioxane or glycol dimethyl ether, ketones such asacetone, methyl ethyl ketone or methyl isobutyl ketone, hydrocarbonssuch as benzene, toluene, xylene, hexane or cyclohexane, chlorinatedhydrocarbons such as dichloromethane or chloroform, or ethyl acetate,acetonitrile, nitromethane, dimethyl sulphoxide, dimethylformamide orsulpholane. It is equally possible to use mixtures of the said solvents.

Possible bases for the process are the customary basic compounds. Thesepreferably include alkali metal or alkaline earth metal hydroxides suchas lithium hydroxide, sodium hydroxide, potassium hydroxide or bariumhydroxide, or alkali metal hydrides such as sodium hydride, or alkalimetal or alkaline earth metal carbonates such as sodium carbonate,sodium bicarbonate, potassium carbonate or calcium carbonate, or alkalimetal alcoholates such as, for example, sodium methanolate, sodiumethanolate, potassium methanolate, potassium ethanolate or potassiumtert.-butylate.

The new cycloalkano[1,2-b]indole-sulphonamides and their salts can beused as active compounds in medicaments. The active compounds exhibit anaction inhibiting platelet aggregation and antagonizing thromboxane A₂.They can preferably be used for the treatment of thromboses,thromboembolisms, ischaemias, and as antiasthmatics and asantiallergics. The new active compounds can be converted in a knownmanner into the customary formulations, such as tablets, capsules,coated tablets, pills, granules, aerosols, syrups, emulsions,suspensions and solutions, using inert, non-toxic, pharmaceuticallysuitable vehicles or solvents. The therapeutically active compoundshould in each case be present in a concentration of about 0.5 to 90% byweight, preferably 5 to 70% by weight, which suffices to achieve thedosage range indicated.

The formulations are prepared, for example, by extending the activecompounds with solvents and/or vehicles, optionally with the use ofemulsifiers and/or dispersing agents, and, for example, when using wateras a diluent, organic solvents can optionally be used as auxiliarysolvents.

Examples of auxiliaries which may be mentioned are: water, non-toxicorganic solvents, such as paraffins (for example petroleum fractions),vegetable oils (for example groundnut oil/sesame oil), alcohols (forexample ethyl alcohol and glycerol) and glycols (for example propyleneglycol and polyethylene glycol), solid vehicles, such as, for example,natural rock powders (for example kaolins, aluminas, talc and chalk),synthetic rock powders (for example highly disperse silica andsilicates) and sugars (for example sucrose, lactose and glucose),emulsifiers (for example polyoxyethylene fatty acid esters,polyoxyethylene fatty alcohol ethers, alkylsulphonates andarylsulphonates), dispersing agents (for example lignin, sulphite wasteliquors, methylcellulose, starch and polyvinylpyrrolidone) andlubricants (for example magnesium stearate, talc, stearic acid andsodium lauryl sulphate).

Administration can be effected in the customary manner, preferablyorally or parenterally, in particular perlingually or intravenously. Inthe case of oral administration, the tablets can, of course, alsocontain, in addition to the vehicles mentioned, additives such as sodiumcitrate, calcium carbonate and dicalcium phosphate, together withvarious additional substances, such as starch, preferably potato starch,gelatine and the like. Furthermore, lubricants such as magnesiumstearate, sodium lauryl sulphate and talc can also be used when makingtablets. In the case of aqueous suspensions and/or elixirs which areintended for oral use, the active compounds can be mixed with variousflavour-improving agents or colorants in addition to the abovementionedauxiliaries.

In the case of parenteral administration, solutions of the activecompounds, employing suitable liquid vehicles, can be used.

In general, it has proved advantageous, in the case of intravenousadministration, to administer amounts of about 0.001 to 1 mg/kg,preferably about 0.01 to 0.5 mg/kg, body weight to achieve effectiveresults, and in the case of oral administration, the dosage is generallyabout 0.01 to 20 mg/kg, preferably 0.1 to 10 mg/kg, of body weight.

Nevertheless, it can at times be advantageous to deviate from theamounts mentioned, and in particular to do so as a function of the bodyweight or of the nature of the administration method, but also as afunction of individual behaviour towards the medicament, or the natureof the formulation of the medicament and the time or interval over whichthe administration takes place. Thus it can suffice in some cases tomanage with less than the abovementioned minimum amount, whilst in othercases the upper limit mentioned must be exceeded. Where relatively largeamounts are administered, it can be advisable to divide these intoseveral individual administrations over the course of the day.

The cycloalkano[1,2-b]indole-sulphonamides according to the inventioncan be used both in human medicine and in veterinary medicine.

PREPARATION EXAMPLES Example 1 3-(Nitromethyl)cyclopentanone ##STR29##

100 g of 2-cyclopentenone are dissolved together with 666 ml ofnitromethane and 5 g of 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) in 1.1 lof isopropanol, and the solution is left to stand at room temperaturefor 5 h. The isopropanol is then substantially distilled in vacuo, andthe residue is dissolved in ethyl acetate and the solution is washedtwice with 0.5 l of dilute sulphuric acid each time. The organic phaseis dried with sodium sulphate and evaporated. In this way 154 g (88% oftheory) of 3-(nitromethyl)cyclopentanone are obtained sufficiently purefor the next reaction.

R_(f) =0.52 CH₂ Cl₂ :CH₃ OH=99:1

Example 2 3-(Aminomethyl)cyclopentanol ##STR30##

57.2 g (0.4 mol) of 3-(nitromethyl)cyclopentanone are dissolved, undernitrogen, in 573 ml of absolute tetrahydrofuran. At 0° C., 800 ml of aone-molar solution of lithium aluminum hydride in tetrahydrofuran areadded dropwise to this solution. After the dropwise addition iscomplete, the mixture is stirred at 0° C. for 1 h. The cooling bath isthen removed, whereupon the temperature of the reaction solution risesto 40° C. After the temperature has fallen to 20° C. the mixture isstirred at this temperature for 1 h. The reaction mixture is cooled to0° C. and then 100 ml of 45% strength sodium hydroxide solution arecautiously added dropwise. After the dropwise addition is complete, thereaction mixture is stirred at room temperature for 1 h, filteredthrough kieselgur, and the kieselgur is washed with 1.5 l oftetrahydrofuran. The combined filtrates are thoroughly evaporated invacuo. In this way 22.5 g (49% of theory) of viscous oily product areobtained.

R_(f) =0.01 CH₂ Cl₂ :CH₃ OH=9:1

Example 3 3-(Benzenesulohonamidomethyl)cyclopentanol ##STR31##

9 g (0.078 mol) of 3-(aminomethyl)cyclopentanol are dissolved togetherwith 13.8 g=10 ml (0.078 mol) of triethylamine in 200 ml oftetrahydrofuran. Then, at 0°-5° C., 7.9 g=10.8 ml (0.078 mol) ofbenzenesulphonyl chloride are added dropwise. After the dropwiseaddition is complete, the mixture is stirred at 0° C. for 1 h. Thereaction mixture is then diluted with 200 ml of methylene chloride, andwashed twice with 150 ml of dilute sulphuric acid each. The organicphase is then extracted twice with 150 ml of 2N sodium hydroxidesolution each time, the combined extracts are acidified withconcentrated hydrochloric acid, and extracted twice with 150 ml ofmethylene chloride each time. The combined methylene chloride phases aredried with sodium sulphate and evaporated in vacuo. In this way 9.1 g(39% of theory) of viscous oily isomer mixture are obtained as theproduct.

R_(f) =0.51 and 0.45 CH₂ Cl₂ :CH₃ OH=95:5

Example 4 3-(Benzenesulphonamidomethyl)cyclopentanone ##STR32##

7.5 g (0.0294 mol) of 3-(benzenesulphonamidomethyl)cyclopentanol aredissolved in 60 ml of glacial acetic acid. At 0°-5° C. 2.79 g (0.0279mol) of chromium trioxide dissolved in 2 ml of water and 8.8 ml ofglacial acetic acid are added dropwise, and then the temperature of thereaction mixture is allowed to rise to room temperature. After thereaction mixture has been stirred at room temperature for 1 hour it isdiluted with 200 ml of ether and washed twice with 150 ml of water eachtime. The organic phase is then extracted twice with 200 ml of 2N sodiumhydroxide solution each time, and the combined sodium hydroxide phasesare acidified with concentrated hydrochloric acid and extracted twicewith 200 ml of methylene chloride each time. The combined methylenechloride phases are dried with sodium sulphate and evaporated in vacuo.In this way 4.4 g (59% of theory) of viscous oily product are obtained.

R_(f) =0.51 CH₂ Cl₂ :CH₃ OH=95:5

Example 5 1-(Benzenesulphonamidomethyl)cyclopentano[1,2-b]indole##STR33##

21 g (0.0826 mol) of 3-(benzenesulphonamidomethyl)cyclopentanone aredissolved together with 9 g (0.0826 mol) of phenylhydrazine in 200 ml ofglacial acetic acid, and the solution is heated under reflux for 4 h.The reaction solution is then diluted with 1.3 l of ether, and 500 ml ofwater are added. While cooling and stirring, the mixture is madealkaline with 45% strength sodium hydroxide solution, and then theorganic phase is separated off. The aqueous phase is extracted once morewith 500 ml of ether, and the combined organic phases are dried withsodium sulphate and evaporated. The residue which is thus obtained ischromatographed on 2 kg of silica gel (Merck 0.04-0.063 mm) with amixture of toluene and ethyl acetate in the ratio 85 to 15. In this waya fraction which, after evaporation, provides 1.9 g (7% of theory) ofcrystalline product is obtained, melting point: 161°-164° C.

R_(f) =0.92 CH₂ Cl₂ :CH₃ OH=95:5

Example 61-[N-(Benzenesulphonyl)-N-(2-cyanoethyl)aminomethyl]-4-(2-cyanoethyl)cyclopentano[1,2-b]indole##STR34##

1.9 g (0.0058 mol) of1-(benzenesulphonamidomethyl)cyclopentano[1,2-b]indole are stirredtogether with 1.83 g=2.3 ml (0.0346 mol) of acrylonitrile and 0.24 g(0.00058 mol) of a 40% strength solution of benzyltrimethylammoniumhydroxide in methanol in 60 ml of dioxane at 60°-70° C. for 2 h. Thenthe reaction mixture is evaporated in vacuo, and the residue is taken upin methylene chloride and the solution is extracted twice with dilutesulphuric acid. The organic phase is washed with saturated bicarbonatesolution, dried with sodium sulphate and evaporated. In this way 2.4 g(95% of theory) of product are obtained as a solid foam.

R_(f) =0.45 CH₂ Cl₂ :CH₃ OH=99:1

Example 71-(Benzenesulphonamidomethyl)-4-(2-carboxyethyl)cyclopentano[1,2-b]indole##STR35##

2.4 9 (0.0055 mol) of1-[N-(benzenesulphonyl)-N-(2-cyanoethyl)aminomethyl]-4-(2-cyanoethyl)cyclopentano[1,2-b]indoleare dissolved in 35 ml of isopropanol, and 55 ml of a 10% strengthpotassium hydroxide solution are added. The reaction mixture is stirredat 70° C. for 4 h, then diluted with 100 ml of water and extracted with100 ml of methylene chloride. The aqueous phase is acidified with dilutesulphuric acid and extracted 3 times with 100 ml of methylene chlorideeach time. The combined organic phases are dried with sodium sulphateand evaporated. The oily residue (1.9 g) is dissolved in methanol, and0.26 g of sodium methylate is added. Evaporation of this solutionprovides 2.0 g (69.2% of theory) of the product as a microcrystallinesodium salt.

R_(f) =0.37 CH₂ Cl₂ :CH₃ OH=95:5

Example 8 3-(4-Fluorophenylsulphonamidomethyl)cyclopentanol ##STR36##

In analogy to the procedure for Example 3, 19.8 g (0.172 mol) of3-(aminomethyl)cyclopentanol are reacted with 28.3 g (0.172 mol) of4-fluorophenylsulphonamide. This results in 17.3 g (36% of theory) ofviscous oily isomer mixture being obtained as the product.

R_(f) =0.53 and 0.46 CH₂ Cl₂ :CH₃ OH=95:5

Example 9 3-(4-Fluorophenylsulphonamidomethyl)cyclopentanone ##STR37##

In analogy to the procedure for Example 4, 17.3 g (0.0638 mol) of3-(4-fluorophenylsulphonamidomethyl)cyclopentanol were oxidized. Thisresults in 14.3 g (83% of theory) of viscous oily product beingobtained.

R_(f) =0.76 CH₂ Cl₂ :CH₃ OH=9:1

Example 10 1-(4-Fluorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole##STR38##

14.3 g (0.0527 mol) of3-(4-fluorophenylsulphonamidomethyl)cyclopentanone were reacted withphenylhydrazine in analogy to Example 5. In this way, afterchromatography on silica gel; 0.67 g (3.7% of theory) ofmicrocrystalline product is obtained.

R_(f) =0.47 CH₂ Cl₂ :CH₃ OH=99:1

Example 114-(2-Cyanoethyl)-1-[N-(4-fluorophenylsulphonyl)-N-(2-cyanoethyl)aminomethyl]cyclopentano[1,2-b]indole##STR39##

0.67 g (0.00195 mol) of1-(4-fluorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole werereacted in analogy to Example 6. In this way 0.83 g (95% of the theory)of product is obtained as a solid foam

R_(f) =0.39 toluene:ethyl acetate=8:2

Example 124-(2-Carboxyethyl)-1-(4-fluorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole##STR40##

0.83 g (0.00184 mol) of4-(2-cyanoethyl)-1-[N-(4-fluorophenylsulphonyl)-N-(2-cyanoethyl)aminomethyl]cyclopentano[1,2-b]indoleis hydrolyzed in analogy to Example 7. In this way 0.67 g (87% oftheory) of crystalline product is obtained as the sodium salt, meltingpoint: 150°-160° C.

R_(f) =0.59 CH₂ Cl₂ :CH₃ OH=9:1

Example 13 3-(4-Chlorophenylsulphonamidomethyl)cyclopentanol ##STR41##

16.8 g (0.146 mol) of 3-(aminomethyl)cyclopentanol are reacted with4-chlorophenylsulphonyl chloride in analogy to Example 3. In this way16.6 g (39% of theory) of viscous oily product are obtained as an isomermixture.

R_(f) =0.46 and 0.44 CH₂ Cl₂ :CH₃ OH=95:5

Example 14 3-(4-Chlorophenylsulphonamidomethyl)cyclopentanone ##STR42##

16.6 g (0.0573 mol) of 3-(4-chlorophenylsulphonamidomethyl)cyclopentanolare oxidized in analogy to Example 4. In this way 13.8 g (83.7% oftheory) of viscous oily product are obtained.

R_(f) =0.7 CH₂ Cl:CH₃ OH=95:5

Example 15 1-(4-Chlorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole##STR43##

13.8 g (0.048 mol) of 3-(4-chlorophenylsulphonamidomethyl)cyclopentanoneare reacted with phenylhydrazine in analogy to Example 5. In this way,after chromatography on silica gel, 1.65 g (9.5% of theory) of productare obtained as a solid foam.

R_(f) =0.46 CH₂ Cl₂ :CH₃ OH=99:1

Example 161-[N-(2-Chlorophenylsulphonyl)-N-(2-cyanoethyl)aminomethyl]-4-(2-cyanoethyl)cyclopentano[1,2-b]indole##STR44##

1.65 g (0.0046 mol) of1-(4-chlorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole arereacted in analogy to Example 6. In this way 1.8 g (84% of theory) ofproduct are obtained as a solid foam.

R_(f) =0.38 toluene:ethyl acetate=8:2

Example 174-(2-Carboxyethyl)-1-(4-chlorophenylsulphonamidomethyl)cyclopentano[1,2-b]indole##STR45##

1.9 g (0.0038 mol) of1-[N-(4-chlorophenylsulphonyl)-N-(2-cyanoethyl)amidomethyl]-4-(2-cyanoethyl)cyclopentano-1,2-b]indoleare hydrolyzed in analogy to Example 7. In this way 1.33 g (81.3% oftheory) of product are obtained as the crystalline sodium salt, meltingpoint: 160° C.

R_(f) =0.55 CH₂ Cl₂ :CH₃ OH=9:1

Example 18 4-(Benzenesulphonamido)cyclohexanol ##STR46##

69 g (0.6 mol) of 4-aminocyclohexanol are reacted with 107 g (0.6 mol)of benzenesulphonyl chloride in analogy to Example 3. In this way 72.8 g(47% of theory) of crystalline product are obtained, melting point:106°-108° C.

R_(f) =0.38 CH₂ Cl₂ :CH₃ OH=95:5

Example 19 4-(Benzenesulphonamido)cyclohexanone ##STR47##

72.8 g (0.285 mol) of 4-(benzenesulphonamido)cyclohexanol are oxidizedin analogy to Example 4. After crystallization from petroleum ether,57.5 g (80% of theory) of product are obtained, melting point: 80°-82°C.

R_(f) =0.66 CH₂ Cl₂ :CH₃ OH=95:5

Example 20 3-(Benzenesulphonamido)-1,2,3,4-tetrahydrocarbazole ##STR48##

57.5 g (0.227 mol) of 4-(benzenesulphonamido)cyclohexanone are reactedwith phenylhydrazine in analogy to Example 5. In this way 41.5 g (56% oftheory) of product crystallized from isopropanol are obtained, meltingpoint: 155° C.

R_(f) =0.82 CH₂ Cl₂ :CH₃ OH=95:5

Example 213-[N-(Benzenesulphonyl)-N-(2-cyanoethyl)amino]-9-(2-cyanoethyl)-1,2,3,4-tetrahydrocarbazole##STR49##

10 g (0.0306 mol) of 3-(benzenesulphonamido)-1,2,3,4-tetrahydrocarbazoleare reacted in analogy to Example 6. In this way 10 g (75% of theory) ofproduct crystallized from ether are obtained, melting point 180°-190° C.

R_(f) =0.29 toluene:ethyl acetate=8:2

Example 223-(Benzenesulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole##STR50##

10 g (0.0263 mol) of3-[N-(benzenesulphonyl)-N-(2-cyanoethyl)amino]-9-(2-cyanoethyl)-1,2,3,4-tetrahydrocarbazoleare hydrolyzed in analogy to Example 7. In this way 7.57 g (68% oftheory) of crystalline product are obtained as the sodium salt, meltingpoint 160°-165° C.

R_(f) =0.44 CH₂ Cl₂ :CH₃ OH=95:5

In analogy to Example 18, the following compounds listed in Table 1 wereprepared: ##STR51##

                  TABLE 1                                                         ______________________________________                                        Example                                                                       No.    X        Yield   R.sub.f                                               ______________________________________                                        23     Cl       80%     0.37   CH.sub.2 Cl.sub.2 :CH.sub.3 OH = 95:5          28     F        75%     0.4    CH.sub.2 Cl.sub.2 :CH.sub.3 OH = 95:5          33     CH.sub.3 48.7%   0.5    CH.sub.2 Cl.sub.2 :CH.sub.3 OH                 ______________________________________                                                                       = 95:5                                     

In analogy to Example 19, the following compounds listed in Table 2 wereprepared: ##STR52##

                  TABLE 2                                                         ______________________________________                                        Ex-                                                                           ample                                 Melting                                 No.   X      Yield   R.sub.f          point:                                  ______________________________________                                        24    Cl     86%     0.77 CH.sub.2 Cl.sub.2 :CH.sub.3 OH                                                              103-4° C.                                                              from                                                                          petro-                                                                        leum                                                                          ether                                 29    F      94%     0.7  CH.sub.2 Cl.sub.2 :CH.sub.3 OH                                                              104-8° C.                                                              from                                                                          petro-                                                                        leum                                                                          ether                                 34    CH.sub.3                                                                             90.7%   0.57 CH.sub.2 Cl.sub.2 :CH.sub.3 OH                      ______________________________________                                                                  = 95:5                                          

In analogy to Example 20, the following compounds listed in Table 3 wereprepared: ##STR53##

                  TABLE 3                                                         ______________________________________                                        Ex-                                                                           ample                                Melting                                  No.   X      Yield   R.sub.f         point:                                   ______________________________________                                        25    Cl     75.4%   0.52 toluene:ethyl 163° C.                                                  acetate 8:2   from                                                                          ether                                 30    F      73%     0.39 CH.sub.2 Cl.sub.2 :CH.sub.3 OH                                                              146-9° C.                                                              from                                                                          ether                                 35    CH.sub.3                                                                             55%     0.42 CH.sub.2 Cl.sub.2 :CH.sub.3 OH                                                              136-8° C.                                                              from                                                                          isopro-                                                                       panol                                 ______________________________________                                    

In analogy to Example 21, the following compounds listed in Table 4 wereprepared: ##STR54##

                  TABLE 4                                                         ______________________________________                                        Ex-                                                                           ample                                Melting                                  No.   X        Yield   R.sub.f       point:                                   ______________________________________                                        26    Cl       47%     0.35   toluene:ethyl                                                                          204-6° C.                                                     acetate 8:2                                                                            from ether/                                                                   isopropanol                            31    F        53%     0.29   toluene:ethyl                                                                          206-8° C                                                      acetate 8:2                                                                            from ether/                                                                   isopropanol                            36    CH.sub.3 85%     0.37   toluene:ethyl                                                                          180-90° C                                                     acetate 8:2                                                                            from ether                             ______________________________________                                    

In analogy to Example 22, the following compounds listed in Table 5 wereprepared: ##STR55##

                  TABLE 5                                                         ______________________________________                                        Ex-                                                                           ample                                Melting                                  No.   X      Yield   Rf              point:                                   ______________________________________                                        27    Cl     89.5%   0.61 CH.sub.2 Cl.sub.2 :CH.sub.3 OH                                                             150° C.                                                                Na salt                                32    F      98.5%   0.57 CH.sub.2 Cl.sub.2 :CH.sub.3 OH                                                             160-70° C.                                                             Na salt                                37    CH.sub.3                                                                             95%     0.53 CH.sub.2 Cl.sub.2 :CH.sub.3 OH                                                             150-60° C.                                                             Na salt                                ______________________________________                                    

Examples 38 and 39

3-r-(4-Fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4a-t,9a-t-hexahydrocarbazole(isomer A) and3-r-(4-fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4,4a-c,9a-c-hexahydrocarbazole(isomer B) ##STR56##

5 g (0.0114 mol) of3-(4-fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazolesodium salt are dissolved in 50 ml of trifluoroacetic acid and, at 0°C., 5.01 g (0.08 mol) of sodium cyanoborohydride are added in portions.The reaction mixture is allowed to reach room temperature, diluted withwater and extracted with 200 ml of ethyl acetate. The ethyl acetatephase is extracted twice with each 100 ml of 2N sodium hydroxidesolution, the combined sodium hydroxide phases are adjusted to pH 5, andextracted three times with each 150 ml of methylene chloride, dried withsodium sulphate and thoroughly evaporated in vacuo. The residue ischromatographed on 500 g of silica gel (Merck, 0.040-0.063 mm) with a100 to 1 mixture of methylene chloride and glacial acetic acid. Twofractions are obtained in this way and, after evaporation, provide 2.87g (60.2% of theory) of isomer (A) and 0.7 g (14.9% of theory) of isomer(B) respectively as a solid foam.

R_(f) of isomer (A): 0.24

    CH.sub.2 Cl.sub.2 :CH.sub.3 COOH=100:2

R_(f) of isomer (B): 0.14

Examples 40 and 41

3-r-(Benzenesulphonamido)-9-(2-carboxyethyl)-1,2,3,4,4a-t,9a-t-hexahydrocarbazole (isomer A) and3-r-(benzenesulphonamido)-9-(2-carboxyethyl)-1,2,3,4,4a-c,9a-c-hexahydrocarbazole (isomer B) ##STR57##

1.18 g (0.0028 mol) of3-(benzenesulphonamido)-9-(2-carboxymethyl)-1,2,3,4-tetrahydrocarbazolesodium salt are reduced in analogy to Example 38. Chromatography resultsin two fractions which, after evaporation, provide 0.45 g (40% oftheory) of isomer A and 0.2 g (18% of theory) of isomer B as a solidfoam.

R_(f) of isomer A: 0.4

    CH.sub.2 Cl.sub.2 :CH.sub.3 COOH=100:4

R_(f) of isomer B: 0.22

Example 42 and Example 433-r-(4-Methylphenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4,4a-t,9a-t-hexahydrocarbazole(isomer A) ##STR58## and3-r-(4-methylphenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4,4a-c,9a-c-hexahydrocarbazole(isomer B) ##STR59##

18.06 g of3-(4-methylphenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazolesodium salt are reduced in analogy to Example 38. Chromatography resultsin two fractions which, after evaporation, provide 3.65 g (20% oftheory) of isomer A as a crystalline residue, melting point: 156°-62°C., and 1.11 g (6% of theory) of isomer B as a solid foam.

R_(f) of isomer A: 0.39

R_(f) of isomer B: 0.20

CH₂ Cl₂ :CH₃ COOH=100:2

Example 443-(4-Chlorophenylsulphonamido)-6-fluoro-1,2,3,4-tetrahydrocarbazole##STR60##

26.5 g of 4-(4-chlorophenylsulphonamido)cyclohexanone are reacted with4-fluorophenylhydrazine in analogy to Example 5. This results in 35.4 g(100% of theory) of product being obtained as a solid foam.

R_(f) =0.53 toluene:ethyl acetate=8:2

Example 453-[N-(4-Chlorophenylsulphonyl)-N-(2-cyanoethyl)amino]-9(2-cyanoethyl)-6-fluoro-1,2,3,4-tetrahydrocarbazole##STR61##

3.4 g of4-(4-chlorophenylsulphonamido)-6-fluoro-1,2,3,4-tetrahydrocarbazole arereacted in analogy to Example 6. In this way 27.6 g (61% of theory) ofproduct are obtained as a solid foam.

R_(f) =0.25 toluene:ethyl acetate=8:2

Example 463-(4-Chlorophenylsulphonamido)-9-(2-carboxyethyl)-6-fluoro-1,2,3,4-tetrahydrocarbazole##STR62## 27.6 g of3-[N-(chlorophenylsulphonyl)-N-(2-cyanoethyl)amino]-9-(2-cyanoethyl)-6-fluoro-1,2,3,4-tetrahydrocarbazoleare hydrolyzed in analogy to Example 7. In this way 25.6 g (100% oftheory) of crystalline product are obtained, melting point: 118°-130° C.

R_(f) =0.52 CH₂ Cl₂ :CH₃ OH=9:1

Example 47 3-(Nitromethyl)cyclohexanone ##STR63## 21.9 g ofcyclohexanone are left to stand together with 175 ml of nitromethane and2.1 g of 5-diazabicyclo[4.3.0.]non-5-ene (DBN) in 250 ml of isopropanolat room temperature for 2 days. The working up is carried out in analogyto the procedure for Example 1 and provides 37.2 g (100% of theory) of3-(nitromethyl)cyclohexanone which is enough for the next reaction.

R_(f) =0.62 CH₂ Cl₂ : CH₃ OH=99:1

Example 48 3-(Aminomethyl)cyclohexanol ##STR64##

37.2 g of 3-(nitromethyl)cyclohexanone are reduced with lithium aluminumhydride in analogy to the procedure for Example 2. In this way 7.5 g(24.5% of theory) of viscous oily 3-(aminomethyl)cyclohexanol areobtained.

R_(f) =0.04 CH₂ Cl₂ :CH₃ OH=9:1

Example 49 3-(4-Fluorophenylsulphonamidomethyl)cyclohexanol ##STR65##

In analogy to the procedure for Example 3 7.5 g of3-(aminomethyl)cyclohexanol are reacted with 11.3 g of4-fluorophenylsulphonamide. This results in 11.05 g (66% of theory) ofviscous oily isomer mixture being obtained as the product.

R_(f) =0.41 and 0.38 CH₂ Cl₂ :CH₃ OH=95:5

Example 50 3-(4-Fluorophenylsulphonamidomethyl)cyclohexanone ##STR66##

In analogy to procedure for Example 4, 11 g of3-(4-fluorophenylsulphonamidomethyl)cyclohexanol are oxidized withchromium trioxide. This results in 9.3 g (86% of theory) of productbeing obtained as a solid foam

R_(f) =0.86 CH₂ Cl₂ :CH₃ OH=9:1

Example 514-(4-Fluorophenylsulphonamidomethyl)-1,2,3,4-tetrahydrocarbazole##STR67##

In analogy to the procedure for Example 5, 9 g of3-(4-fluorophenylsulphonamidomethyl)cyclohexanone are reacted withphenylhydrazine. This results in 9 g of crude product which ischromatographed on 1 kg of silica gel (Merck 0.04-0.063 mm) in a mixtureof toluene and ethyl acetate in the ratio 8 to 2. One fraction from thisresults, after evaporation, in 0.8 g (7.2% of theory) of product as asolid foam.

R_(f) : 0.44 toluene: ethyl acetate=8:2

Example 529-(2-Cyanoethyl)-4-[N-(4-fluorophenylsulphonyl)-N-(2-cyanoethyl)aminomethyl]-1,2,3,4-tetrahydrocarbazole##STR68##

In analogy to the procedure for Example 6 0.8 g of4-(4-fluorophenylsulphonamidomethyl)-1,2,3,4-tetrahydrocarbazole isreacted with acrylonitrile. This results in 0.91 g (88% of theory) ofproduct being obtained as an oil.

R_(f) =0.37 toluene:ethyl acetate=8:2

Example 539-(2-Carboxyethyl)-4-(4-fluorophenylsulphonamidomethyl)-1,2,3,4-tetrahydrocarbazole##STR69##

0.91 g of9-(2-cyanoethyl)-4-[N-(4-fluorophenylsulphonyl)-N-(2-cyanoethyl)aminomethyl]-1,2,3,4-tetrahydrocarbazoleis hydrolyzed in analogy to Example 7. In this way 0.77 g (89% oftheory) of crystalline product is obtained as the sodium salt.

Melting point: 160° C.

R_(f) =0.57 CH₂ Cl₂ :CH₃ OH=9:1

Example 54 4-N-Acetamidocyclohexanol ##STR70##

300 g of paracetamol in 750 ml of ethanol are hydrogenated on 30 g ofRaney nickel at 180° C. and under 100 bar. After uptake of hydrogen iscomplete, the catalyst is removed by filtration and, after addition of30 g of Raney nickel, hydrogenation is repeated at 180° C. and under 100bar of excess pressure. The catalyst is then removed by filtration, thefiltrate is evaporated in vacuo, and 200 ml of acetone are added to thestill moist residue and stirred. After the crystals have been filteredoff with suction, the mother liquor is concentrated further, thecrystals which have separated out are once more filtered off withsuction, and the mother liquor is again concentrated. The total obtainedtogether with this 3rd batch is 342. 4 g (80.8% of theory) of theproduct.

Melting point: 100°-103° C.

Example 55 3-Amino-1,2,3,4-tetrahydrocarbazole (racemate) ##STR71##

50 g (0.318 mol) of 4-N-acetamidocyclohexanol are dissolved in 400 ml ofglacial acetic acid and, while stirring at room temperature, a solutionof 31.8 g (0.318 mol) of chromium trioxide in a mixture of 26 ml ofwater and 105 ml of glacial acetic acid is added. This resulted in thetemperature of the reaction solution rising to 60° C. The reactionmixture was stirred for 3 hours, and then 45.7 g (0.423 mol) ofphenylhydrazine were added This results in heating of the reactionsolution to 80° C. and initial evolution of nitrogen. The reactionmixture is then heated under reflux for 2.5 hours. After the reactionmixture has been cooled, 500 ml of concentrated hydrochloric acid and 59ml of thioglycolic acid are added and the mixture is heated underreflux, under nitrogen, for 16 hours. After cooling the mixture it isdiluted with 500 ml of ethyl acetate and, while cooling, it is madealkaline with 45% strength sodium hydroxide solution. The precipitatedchromium hydroxide is removed by filtration with suction through a layerof kieselguhr and is washed with a mixture of methylenechloride/methanol in the ratio 9:1. The organic phase is separated offfrom the filtrate, and the aqueous phase is extracted 3 more times withethyl acetate. The combined organic phases are washed twice with 2Nsodium hydroxide solution, and then extracted twice with 1 l of 2Nsulphuric acid each time. The acidic aqueous phase is made alkaline with45% strength sodium hydroxide solution and extracted 3 times with 1 l ofmethylene chloride each time. The combined methylene chloride phases aredried with sodium phosphate and evaporated. 300 ml of ether and 50 ml ofisopropanol are added to the residue, and the mixture is stirred. Theprecipitated product is filtered off with suction, washed with ether anddried in vacuo. 28.6 g (48.3% of theory) of product are obtained.

Melting point: 174°-176° C.

Example 563-[2S-(Chloroacetamido)-3-phenylpropionamido]-1,2,3,4-tetrahydrocarbazole(diastereomer mixture) ##STR72##

43 g (0.231 mol) of 3-amino-1,2,3,4-tetrahydrocarbazole and 55.87 g(0.231 mol) of N-chloroacetyl-L-phenylalanine are suspended in 1.5 1 ofmethylene chloride under nitrogen and, at 0° C., 115.2 ml (0.832 mol) oftriethylamine are added. Then, at -20° C., 150 ml (0.231 mol) of a 50%strength solution of propanephosphonic anhydride in methylene chlorideare added dropwise to the reaction mixture. It is stirred at -20° C. for30 minutes and then stirred at 0° C. for 1.5 hours. For working up, thereaction mixture is washed with 1 l of 2N sulphuric acid, with 1 l ofwater and twice with 1 l of saturated bicarbonate solution each time.After drying with sodium sulphate and evaporation, 100 g of solidresidue are obtained.

Example 57 and Example 583-[2S-(Chloroacetamido)-3-phenylpropionamido]-1,2,3,4-tetrahydrocarbazole(diastereomer A and diastereomer B)

(a) Diastereomer separation by column chromatography

100 g of crude product from Example 56 are chromatographed on 2.5 kg ofsilica gel (0.063 to 0.2 mm, Merck) with a mixture of toluene/ethylacetate in the ratio 6:4 as mobile phase. In this way 2 fractions areobtained, of which the first provides, after evaporation, 34 g (35.9% oftheory) of diastereomer A (Example 57).

Melting point: 217°-220° C.

The second fraction provides, after evaporation, 24.3 g (25.7% oftheory) of the other diastereomer B (Example 58).

Melting point: 193°-195° C.

Rotation of diastereomer A: [α]²⁰ =32.59° (CH₃ OH) (Example 57).

Rotation of diastereomer B: [α]²⁰ =5.09° (CH₃₀ H) (Example 58).

(b) Diastereomer separation by crystallization

11.5 g of crude product from Example 56 are stirred in a mixture ofether and isopropanol. The crystals were filtered off with suction andheated under reflux in 40 ml of acetone for 3 hours. After cooling andleaving to stand overnight, the product was filtered off with suctionand washed with acetone. In this way 1.2 g (5.5% of theory) of purediastereomer A (Example 57) are obtained.

Example 59 3-Amino-1,2,3,4-tetrahydrocarbazole (enantiomer A) ##STR73##

24.1 g (0.059 mol) of diastereomer 57 are dissolved in 460 ml of glacialacetic acid. 460 ml of concentrated hydrochloric acid and 24 ml ofthioglycolic acid are added and heated under reflux, under nitrogen, for3 days. The reaction mixture is then diluted with 200 ml of water and,while cooling, is adjusted to pH 5 with 45% strength sodium hydroxidesolution. It is then extracted twice with 1.5 l of ethyl acetate eachtime, and the aqueous phase is then made alkaline with 45% strengthsodium hydroxide solution and extracted 3 times with 1.5 l of ethylacetate each time. The ethyl acetate extracts are combined, dried withsodium sulphate and evaporated. The residue is stirred in 150 ml ofether. The precipitated product is filtered off with suction and driedin vacuo. 7.8 g (71.3% of theory) of enantiomer A are obtained. Meltingpoint: 160°-166° C. Rotation [α]²⁰ =78.38 ° (DMSO+10% water)

Example 60 3-Amino-1,2,3,4-tetrahydrocarbazole (enantiomer B) ##STR74##

Enantiomer B is prepared by hydrolysis of 58 in analogy to the procedurefor 59 from 57.

Melting point: 162°-167° C.

Rotation [α]²⁰ =-78.11° (DMSO+10% H₂ O)

Example 61 3,3-Ethylenedioxy-1,2,3,4-tetrahydrocarbazole ##STR75##

77.2 g (0.5 mol) of 1,4-cyclohexanedione monoethylene ketal aredissolved together with 48.4 ml (0.5 mol) of phenylhydrazine in 2 l ofmethylene chloride, and 300 g of magnesium sulphate are added, and themixture is stirred for 30 min. The magnesium sulphate is then filteredoff with suction, washed with methylene chloride, and the filtrate isevaporated. The residue is taken up in 1.5 l of benzene, and 62.1 g(0.46 mol) of anhydrous zinc chloride are added and the mixture isheated under reflux with a water separator for 3 h. The reactionsolution is then concentrated, 2N sodium hydroxide solution is added,and the mixture is extracted 3 times with ethyl acetate. The combinedethyl acetate phases are dried with sodium sulphate and evaporated. Theresidue crystallizes from a little ether. In this way 3.5 g (72% oftheory) of the product are obtained.

Melting point: 145°-146° C.

Example 62 1,2,4,9-Tetrahydrocarbazol-3-one ##STR76##

165 g (0.72 mol) of 3,3-ethylenedioxy-1,2,3,4-tetrahydrocarbazole aredissolved in 2 l of acetone, and 3 g of p-toluenesulphonic acid areadded. After the reaction solution has been heated under reflux for 4 hit is concentrated, 2 l of ethyl acetate are added, and the mixture isextracted 3 times with 1 l of saturated bicarbonate solution each time.The organic phase is dried with sodium sulphate and evaporated. Theresidue crystallizes from ether. In this way 118.7 g (89.1% of theory)of the product are obtained.

Melting point: 145°-148° C.

Example 63 3-(1S-Phenylethylamino)-1,2,3,4-tetrahydrocarbazole ##STR77##

11.06 g (0.0595 mol) of 1,2,4,9-tetrahydrocarbazol-3-one are heatedtogether with 7.78 g (0.065 mol) of 1S-phenylethylamine in 300 ml ofbenzene under reflux with a water separator for 1 h. After removal ofthe benzene by evaporation, the residue is dissolved in 50 ml ofmethylene chloride, and the solution is added dropwise to a solution of15.3 g (0.0595 mol) of tetrabutylammonium borohydride in 120 ml ofmethylene chloride at -50° C. The reaction mixture is allowed to returnto room temperature within 1 h, 6 ml of methanol are added, and 120 mlof 2N sulphuric acid are added cautiously (evolution of hydrogen). Afterstirring at room temperature for 1 h, the crystals which have separatedout are filtered off with suction and washed twice with water and oncewith methylene chloride. After drying under high vacuum, 0.16 g (39.7%of theory) of the product is obtained as hydrogen sulphate.

Melting point: 160°-170° C.

Rotation: [α]²⁰ =26.36° (CH₃ OH/H₂ O=80:20)

Example 64 3-Amino-1,2,3,--tetrahydrocarbazole (enantiomer A) ##STR78##[Example 64, prepared by process B, is identical to Example 59]

10 g of the hydrogen sulphate obtained from Example 53 are, forconversion into the hydrochloride, suspended in 50 ml of methanol, and30 ml of 2N sodium hydroxide solution are added, and the mixture isextracted with ethyl acetate. The organic phase is evaporated, and theresidue is dissolved in 50 ml of methanol, and 20 ml of concentratedhydrochloric acid are added. The hydrochloride precipitates out onconcentration in vacuo. After filtration with suction, washing withwater and drying in vacuo, 7.6 g of hydrochloride are obtained. These7.6 g (0.023 mol) of hydrochloride are heated together with 7.17 g(0.115 mol) of ammonium formate and 7.2 g of 10% palladium on activecharcoal in 80 ml of dry dimethylformamide under reflux (under nitrogen)for 20 min. After cooling, the mixture is diluted with water, and thecatalyst is filtered off with suction and washed with water. Thecombined filtrates are acidified with 2N sulphuric acid and extractedtwice with ethyl acetate. The aqueous phase is made alkaline with 2Nsodium hydroxide solution and extracted three times with ethyl acetate.The organic phases are dried with sodium sulphate and evaporated. Theresidue is further evaporated under high vacuum to removedimethylformamide. 3 g (70% of theory) of crystalline enantiomer A areobtained from ether.

Melting point: 160°-166° C.

Rotation [α]²⁰ =78.38° (DMSO+10% water)

Example 65 3-(4-Fluorophenylsulphonamido)-1,2,3,4-tetrahydrocarbazole(enantiomer A) ##STR79##

3.72 g (0.02 mol) of Example 59 are suspended together with 3 ml (0.022mol) of triethylamine in 30 ml of methylene chloride and, while cooling,3.9 g (0.02 mol) of 4-fluorobenzenesulphonyl chloride are added. Thereaction mixture is dissolved at room temperature for 1 h and thenstirred with 200 ml of ethyl acetate and extracted twice with 2Nsulphuric acid and twice with 2N sodium hydroxide solution. The organicphase is dried with sodium sulphate and evaporated. Ether is added tothe solid residue which is crystallized. 5.8 g (84% of theory) of theproduct are obtained.

Melting point: 150°-152° C.

Rotation: [α]²⁰ =50.43° (CHCl₃)

Example 66 3-(4-Fluorophenylsulphonamido)-1,2,3,4-tetrahydrocarbazole(enantiomer B) ##STR80##

Enantiomer B is prepared from Example 60 in analogy to the preparationof Example 65 from Example 59.

Melting point: 150°-152° C.

Rotation: [α]²⁰ =-48.99° (CHCl₃)

Example 673-[N-(4-Fluorophenylsulphonyl)amino]-9-(2-cyanoethyl)-1,2,3,4-tetrahydrocarbazole(enantiomer A) ##STR81##

5. 16 g (0.015 mol) of Example 65 are dissolved in 200 ml of drydimethylformamide under nitrogen, and 0.5 g (0.0165 mol) of sodiumhydride with 20% spindle oil is added in portions. Once evolution ofhydrogen is complete, 2 ml (0.03 mol) of acrylonitrile are added to thereaction mixture. After stirring at room temperature for 1 h, 0.5 ml ofacrylonitrile is once more added, and the mixture is stirred at roomtemperature for 1 h. It is diluted with 1 l of ethyl acetate andextracted three times with water. The ethyl acetate phase is dried withsodium sulphate and evaporated. In this way 7.8 g of crude product isobtained and is chromatographed on 150 g of silica gel (0.063 to 0.2 mm,Merck) with a mixture of toluene/ethyl acetate in the ratio 1:1. Afraction which, after evaporation, provides 5.8 g (86% of theory) ofproduct as a solid foam is obtained.

The bis-cyanoethyl adduct(3-[N-(4-fluorophenylsulphonyl)-N-(2-cyanoethyl)amino]-9-(2-cyanoethyl)-1,2,3,4-tetrahydrocarbazole)is produced under the conditions indicated in Example 6.

Example 683-[N-(4-Fluorophenylsulphonyl)-N-(2-cyanoethyl)amido]-9-(2-cyanoethyl)-1,2,3,4-tetrahydrocarbazole(enantiomer B) ##STR82##

Example 68 is prepared from Example 66 in analogy to the preparation ofExample 67 from Example 65.

Example 69(+)-3-(4-Fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole##STR83##

5.8 g (0.0128 mol) of Example 67 are dissolved in 60 ml of isopropanol,130 ml of 10% strength potassium hydroxide solution are added and, afterheating under reflux for 16 h, the mixture is cooled, diluted with waterand extracted with ethyl acetate. The aqueous phase is concentrated invacuo and then acidified dropwise with concentrated hydrochloric acidwhile stirring vigorously. The acid which precipitates out during thisis filtered off with suction, washed with water and thoroughly dried invacuo. 4.4 g (86.6% of theory) of the product are obtained.

Melting point: 85°-95° C.

Rotation [α]²⁰ =42.55° (CHCl₃)

Example 70(-)-3-(4-Fluorophenylsulphonamido)-9-(2-carboxyethyl)-1,2,3,4-tetrahydrocarbazole##STR84##

Example 70 is prepared from Example 68 in analogy to the preparation ofExample 69 from Example 67.

Melting point: 85°-95° C.

Rotation: [α]²⁰ =-37.83° (CHCl₃)

Example 71 (+)-3-Amino-1,2,3,4-tetrahydrocarbazole ##STR85##

18.6 g (0.1 mol) of racemic 3-amino-1,2,3,4-tetrahydrocarbazole areheated together with 15.2 g (0.1 mol) of (+)-mandelic acid in 100 ml oftetrahydrofuran under reflux. Once a clear solution has been obtained,it is allowed to cool and a spatula tip of the (+)-mandelic acid salt of(+)-3-amino-1,2,3,4-tetrahydrocarbazole (enantiomer A, Example 59) isadded as seed crystals. The mixture is stirred overnight, and thecrystals which have separated out are filtered off with suction. In thisway 6.05 g of enantiomerically enriched material are obtained. 4.7 g ofthese crystals are dissolved in 330 ml of boiling methyl isobutyl ketoneand, after cooling slightly, the solution is seeded and stirred ascooling is continued. After filtration with suction and washing withmethyl isobutyl ketone, 3.4 g of (+)-3-amino-1,2,3,4-tetrahydrocarbazoleare obtained as the (+)-mandelic acid salt.

Example 72

For determination of the action inhibiting platelet aggregation use wasmade of blood from healthy subjects of both sexes. One part of 3.8%strength aqueous sodium citrate solution was mixed as anticoagulant with9 parts of blood. Platelet-rich citrated plasma (PRP) is obtained fromthis blood by centrifugation (Jurgens/Beller, Klinische Methoden derBlutgerinnungsanalyse (Chemical Methods of Blood Coagulation Analysis);published by Thieme, Stuttgart, 1959).

For these investigations, 0.8 ml of PRP and 0.1 ml of the activecompound solution were preincubated in a waterbath at 37° C.Subsequently the platelet aggregation was determined by theturbidometric method in an aggregometer at 37° C. (Born, G. V. R., J.Physiol. (London), 162, 1962 and Therapeutische Berichte 47, 80-86,1975). For this purpose, 0.1 ml of collagen, an aggregation-initiatingagent, was added to the preincubated sample. The change in the opticaldensity of the sample of PRP was recorded during a period of 6 minutes,and the deflection after 6 minutes was determined. For this purpose, thepercentage inhibition compared with the control is calculated.

    ______________________________________                                                              Limiting concentra-                                     Cycloalkanol[1,2-b] indolesulphonamide                                                              tion for inhibition                                     of Example No.        (mg/kg)                                                 ______________________________________                                         6                    10-3                                                    12                    0.03-0.01                                               17                    0.03-0.01                                               22                    3-1                                                     27                    0.1-0.03                                                32                     0.1-0.03                                               38                     1.0-0.3                                                39                    0.3-0.1                                                 40                    1.0-0.3                                                 41                    0.3-0.1                                                 46                     0.1-0.01                                               52                    0.3-0.1                                                 ______________________________________                                    

We claim:
 1. A cycloalkano[1,2-b]indole-sulphonamide of the formula##STR86## in which R¹ represents hydrogen, halogen, trifluoromethyl,carboxyl or alkoxycarbonyl; or represents a group of the formula--S(O)_(m) R³, in which R³ denotes alkyl or aryl, and m denotes one ofthe numbers 0, 1 or 2; or represents a group of the formula ##STR87## inwhich R⁴ and R⁵ each independently represent hydrogen, alkyl, aryl,aralkyl or acetyl; or represents a group of the formula --OR⁶, in whichR⁶ denotes hydrogen, alkyl, aryl, aralkyl, alkyl-SO₂ --, aryl--SO₂ --,aralkyl--SO₂ -- or trifluoromethyl; or represents alkyl, alkenyl orcycloalkyl, each of which is optionally substituted by carboxyl,alkoxycarbonyl, halogen, hydroxyl, alkoxy, alkylthio or cyano, R²represents aryl which is optionally substituted up to 5 times byhalogen, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio,alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, alkylthio, hydroxyl,carboxyl, alkoxycarbonyl, phenyl, phenoxy, benzyloxy, benzylthio or by agroup of the formula ##STR88## in which R⁴ and R⁵ have theabovementioned meaning, x represents the number 1, 2 or 3, and yrepresents the number 0 or 1, where appropriate in an isomeric form, andsalts thereof.
 2. A cycloalkanol[1,2-b]indole-sulphonamide according toclaim 1, in whichR¹ represents hydrogen, fluorine, chlorine, bromine,trifluoromethyl, carboxyl or alkoxycarbonyl having 1 to 6 carbon atoms;or represents a group of the formula

    --S(O).sub.m R.sup.3

in which R³ denotes alkyl having 1 to 6 carbon atoms or phenyl, and mdenotes a number 0 or 2; or represents a group of the formula ##STR89##in which R⁴ and R⁵ each independently denote hydrogen, alkyl having 1 to6 carbon atoms, phenyl, benzyl or acetyl; or represents a group of theformula --OR⁶, in which R⁶ denotes hydrogen, alkyl having 1 to 6 carbonatoms, phenyl, phenyl--SO₂ --, methyl--SO₂ --, ethyl--SO₂ -- ortrifluoromethyl, or represents alkyl having 1 to 6carbon atoms, alkenylhaving 2 to 6 carbon atoms, cyclopentyl, or cyclohexyl, each of which isoptionally substituted by carboxyl, methoxycarbonyl, ethoxycarbonyl,fluorine, chlorine, bromine, hydroxyl, alkyloxy having 1 to 6 carbonatoms or cyano, R² represents phenyl which is optionally substituted upto three times by fluorine, chlorine, bromine, cyano, trifluoromethyl,trifluoromethoxy, trifluoroemthylthio, alkyl having 1 to 6 carbon atoms,carboxymethyl, carboxyethyl, methoxymethyl, ethoxymethyl, methoxyethyl,ethoxyethyl, alkoxy having 1 to 6 carbon atoms, alkylthio having 1 to 6carbon atoms, hydroxyl, carboxyl, alkoxycarbonyl having 1 to 6 carbonatoms, phenyl, phenoxy, benzyloxy, benzylthio or by the group ##STR90##in which R⁴ and R⁵ have the meaning already indicated, x represents thenumber 1, 2 or 3, and y represents the number 0 or 1, where appropriatein an isomeric form, and salts thereof.
 3. Acycloalkano[1,2-b]indole-sulphonamide according to claim 1, in whichR¹represents hydrogen, fluorine, chlorine, bromine, trifluoromethyl,methylthio, ethylthio, methylsulphonyl, phenylthio, phenylsulphonyl,amino, dimethylamino, diethylamino or acetylamino; or represents a groupof the formula

    --OR.sup.6

in which R⁶ denotes hydrogen, C₁ -C₄ -alkyl, phenyl or benzyl; orrepresents C₁ -C₄ -alkyl, R² represents phenyl which is substituted upto three times, identically or differently, by fluorine, chlorine,bromine, cyano, trifluoromethyl, trifluoromethoxy, C₁ -C₄ -alkyl, C₁ -C₄-alkoxy, methylthio, hydroxyl, methoxycarbonyl, ethoxycarbonyl,dimethylamino, acetylamino, or diethylamino, x represents the number 1or 2, and y represents the number 0 or 1, where appropriate in anisomeric form, or saIts thereof.
 4. A (+) or (-) isomer of acycloalkano-[1,2-b]-indolesulphonamide according to claim 1, of theformula ##STR91## in which R¹ represents hydrogen, fluorine, methyl,methoxy, benzyloxy or hydroxyl,R² represents phenyl which is substitutedby fluorine, chlorine, trifluoromethyl, methyl, ethyl, propyl, isopropylor methoxy, and y represents the number 0 or 1, and salts thereof.
 5. Anisomer according to claim 4 which is(+)-3-(4-fluoro-phenyl-sulphonamido)-9-(2-carboxy-ethyl)-1,2,3,4-tetrahydrocarbazole.6. An isomer according to claim 4 which is(-)-3-(4-fluorophenyl-sulphonamido)-9-(2-carboxy-ethyl)-1,2,3,4-tetrahydrocarbazole.7. A medicament useful as an inhibitor of platelet aggregation or anantagonist of thromboxane A₂ containing an effective amount of acycloalkano[1,2-b]sulphonamide according to claim 1 and apharmaceutically acceptable carrier.
 8. A medicament according to claim7 containing 0.5 to 50% by weight of the cycloalkano indolesulphonamide.9. A method of inhibiting platelet aggregation or antagonizingthromboxane A₂ comprising administering to a patient in need of suchtreatment an amount effective to inhibit aggregation platelets or toantagonize thromboxane A₂ of a cycloalkano-indole-sulphonamide accordingto claim 1.